Nykode Therapeutics AS Ordinary Shares VACBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.45
- Day Range
- $0.30–0.30
- 52-Week Range
- $0.16–0.45
- Bid/Ask
- $0.10 / $0.60
- Shares Outstanding
- 391.55M
- Market Cap
- $97.11M
- Volume/Avg
- 1,000 / 1,375
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 59
- Website
- https://www.nykode.com
Valuation
|
Metric
|
VACBF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
VACBF
Financial Strength
|
Metric
|
VACBF
|
|---|---|
Quick Ratio | 11.52 |
Current Ratio | 11.52 |
Interest Coverage | −257.28 |
Quick Ratio
VACBF
Profitability
|
Metric
|
VACBF
|
|---|---|
Return on Assets (Normalized) | −22.61% |
Return on Equity (Normalized) | −24.37% |
Return on Invested Capital (Normalized) | −25.92% |
Return on Assets
VACBF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|fGmJlh | LOCK|F<&@v | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Ws^z&M | LOCK|YV#$ | $83B | |||
| Moderna Inc
MRNA
| LOCK|>Qclv! | LOCK|z# | $80B | |||
| argenx SE ADR
ARGX
| LOCK|??!zJMD | LOCK|sC# | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%zkm@d | LOCK|k? | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<#@PW?M | LOCK|DLrkx | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|sr#B%<fB | LOCK|fthr | $28B | |||
| Incyte Corp
INCY
| LOCK|^!wxyp | LOCK|k? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|mRbqfM | LOCK|s$H | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<@SgW$j | LOCK|^Dg | $14B |
United States